"Pyridones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridine derivatives with one or more keto groups on the ring.
| Descriptor ID |
D011728
|
| MeSH Number(s) |
D03.383.725.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridones".
Below are MeSH descriptors whose meaning is more specific than "Pyridones".
This graph shows the total number of publications written about "Pyridones" by people in this website by year, and whether "Pyridones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 4 | 2 | 6 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 7 | 9 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 8 | 11 |
| 2020 | 5 | 5 | 10 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 5 | 5 |
| 2023 | 2 | 8 | 10 |
| 2024 | 7 | 8 | 15 |
| 2025 | 1 | 3 | 4 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridones" by people in Profiles.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026 Mar 04; 81(4).
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis. Am J Kidney Dis. 2026 Mar; 87(3):313-323.
-
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii. Diagn Microbiol Infect Dis. 2025 Nov; 113(3):116991.
-
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20?years in sub-Saharan Africa. Contemp Clin Trials. 2025 Aug; 155:107963.
-
An audit of the HIV drug resistance testing program in Malawi. Malawi Med J. 2025 03; 37(1):16-22.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.
-
Emerging integrase resistance in an international perinatal virtual clinic. AIDS. 2025 Mar 01; 39(3):276-280.